March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Estimation Of Cancer Risk Associated With Metastatic Surveillance Imaging For Choroidal Melanoma
Author Affiliations & Notes
  • Joanne C. Wen
    Ophthalmology, Jules Stein Eye Institute at UCLA, Los Angeles, California
  • Victor Sai
    Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
  • Bradley R. Straatsma
    Ophthalmology, Jules Stein Eye Institute at UCLA, Los Angeles, California
  • Tara A. McCannel
    Ophthalmology, Jules Stein Eye Institute at UCLA, Los Angeles, California
  • Footnotes
    Commercial Relationships  Joanne C. Wen, None; Victor Sai, None; Bradley R. Straatsma, None; Tara A. McCannel, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3419. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joanne C. Wen, Victor Sai, Bradley R. Straatsma, Tara A. McCannel; Estimation Of Cancer Risk Associated With Metastatic Surveillance Imaging For Choroidal Melanoma. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3419.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To estimate the lifetime attributable risk (LAR) of cancer incidence associated with whole-body fluorine 18 (18F)-fluorodeoxyglucose (FDG) positron emission tomographic (PET)/computerized tomography (CT) in the surveillance for choroidal melanoma metastases.

 
Methods:
 

Organ doses from whole-body PET/CT studies of standardized male and female phantoms were estimated using a combination of Monte Carlo simulation methods and by multiplying the 18F-FDG radioactivity (370 MBq) with dose coefficients. Lifetime attributable risks of cancer incidence were calculated using the approach described in the Biological Effects of Ionizing Radiation VII Report.

 
Results:
 

The effective dose of a whole-body PET/CT scan was estimated to be 24.05 mSv per scan. In a 50-year-old patient, an annual PET/CT each year for 5 years carries a lifetime risk of cancer of 0.6% for men and 0.8% for women. This risk increases to 1.3% and 1.6% for men and women respectively if this annual protocol is continued for 10 years. If the frequency of surveillance is increased to every 6 months and continued for 10 years, the lifetime risk further increases to 2.6% and 3.2% for men and women respectively. The risk was found to be higher in patients diagnosed at a younger age and in female patients. The lifetime risk of cancer was estimated to be as high as 4.7% for a 30-year-old female receiving a PET/CT scan every 6 months for 10 years.

 
Conclusions:
 

Whole-body PET/CT imaging in choroidal melanoma surveillance is associated with a nonnegligible lifetime risk of cancer. These risks should be considered when counseling patients with choroidal melanoma.

 
Keywords: melanoma • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • tumors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×